News & Events
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults
Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with...
READ MOREFDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Event Date: Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval of PALSONIFY. Live & Archived Webcast: https://events.q4inc.com/attendee/443074040 Dial-in Details: Domestic: 1-833-470-1428International: 1-646-844-6383Conference ID: 120796
READ MORECrinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an...
READ MORECrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor...
READ MORECrinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.
READ MOREWebcast: Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results
Event Date: August 7, 2025
READ MORECrinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Crinetics announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly at ENDO 2025.
READ MORECrinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO – July 11, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results...
READ MORECrinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.